Page last updated: 2024-11-11

beraprost

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

beraprost: stable prostacyclin analog; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

beraprost : An organic heterotricyclic compound that is (3aS,8bS)-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan in which the hydrogens at positions 1R, 2R and 5 are replaced by (3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl, hydroxy and 3-carboxypropyl groups, respectively. It is a prostaglandin receptor agonist which is approved to treat pulmonary arterial hypertension in Asia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6917951
CHEMBL ID1207745
CHEBI ID135633
SCHEMBL ID34593
SCHEMBL ID16904620
MeSH IDM0138550

Synonyms (36)

Synonym
ml-1229
88430-50-6
(+-)-(1r,2r,3as,8bs)-2,3,3a,8b-tetrahydro-2-hydroxy-1-((e)-(3s,4rs)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1h-cyclopenta(b)benzofuran-5-butyric acid
2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2,3,3a,8b-tetrahydro-1h-cyclopenta(b)benzofuran-5-butanoic acid
beraprostum [inn-latin]
beraprost [usan:inn]
ml 1229
mdl 201229
1h-cyclopenta(b)benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-
beraprost
mdl201229
4-{(1r,2r,3as,8bs)-2-hydroxy-1-[(1e,3s)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1h-benzo[b]cyclopenta[d]furan-5-yl}butanoic acid
beraprostum
ml1229
CHEBI:135633
mdl-201229
4-[(1r,2r,3as,8bs)-1-[(e,3s)-4-methyl-3-oxidanyl-oct-1-en-6-ynyl]-2-oxidanyl-2,3,3a,8b-tetrahydro-1h-cyclopenta[b][1]benzofuran-5-yl]butanoic acid
A842581
4-[(1r,2r,3as,8bs)-2-hydroxy-1-[(e,3s)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1h-cyclopenta[b]benzofuran-5-yl]butanoic acid
trk-100stp free acid
CHEMBL1207745
unii-35e3njj4o6
35e3njj4o6 ,
beraprost [inn]
(+/-)-(1r,2r,3as,8bs)-2,3,3a,8b-tetrahydro-2-hydroxy-1-((e)-(3s,4rs)-3-hydroxy-4-methyl-1-octen-6-ynyl)-1h-cyclopenta(b)benzofuran-5-butyric acid
beraprost [who-dd]
rac-4-((1r,2r,3as,8bs)-2-hydroxy-1-((1e,3s,4rs)-3-hydroxy-4-methyloct-1-en-6-ynyl)-2,3,3a,8b-tetrahydro-1h-cyclopenta(b)(1)benzofuran-5-yl)butanoic acid
beraprost [mi]
beraprost [usan]
SCHEMBL34593
(1r,2r,3as,8bs)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3s,1e)-3-hydroxy-4-methyl-1-octene-6-ynyl]-5-(3-carboxypropyl)-1h-cyclopenta[b]benzofuran
CTPOHARTNNSRSR-APJZLKAGSA-N
DTXSID7049136
SCHEMBL16904620
rel-4-((1r,2r,3as,8bs)-2-hydroxy-1-((3s,e)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)-2,3,3a,8b-tetrahydro-1h-cyclopenta[b]benzofuran-5-yl)butanoic acid
218432-32-7

Research Excerpts

Overview

Beraprost is a prostacyclin analogue and IP receptor agonist which is approved to treat pulmonary arterial hypertension (PAH) in Asia. Beraprost sodium (BPS) is a stable orally active prostacyClin analogue with vasodilatory and anti-platelet effects.

ExcerptReferenceRelevance
"Beraprost sodium is an oral prostacyclin analog that was first approved in 1992 (Japan) for the treatment of peripheral vascular disorders. "( Study on bioequivalence of beraprost in healthy volunteers by liquid chromatography with tandem mass spectrometry.
Harahap, Y; Lusthom, W; Prasaja, B; Puspanegara, G; Safira, F; Sandra, M; Sofiana, A, 2019
)
2.25
"Beraprost is a prostacyclin analogue and IP receptor agonist which is approved to treat pulmonary arterial hypertension (PAH) in Asia. "( Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension.
Clapp, LH; Moledina, S; Norel, X; Patel, JA; Shen, L; Sista, P; von Kessler, K; Whittle, BJ, 2019
)
2.23
"Beraprost sodium (BPS) is a prostacyclin analog with vasodilatory and antiplatelet effects."( Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy.
Kim, DK; Kim, SG; Lee, YK; Lim, CS; Na, KY, 2013
)
1.51
"Beraprost sodium (BPS) is a prostaglandin analogue. "( Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy.
Chen, YQ; Deng, L; Guan, J; Li, L; Long, L; Tian, LH; Yin, Y; Zhang, CX, 2014
)
2.23
"Beraprost sodium (BPS) is an orally active prostacyclin (PGI2) analogue demonstrating prevention of the progression of chronic kidney disease (CKD) in various animal models by maintaining renal blood flow and attenuating renal ischemic condition."( Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial.
Fujita, T; Gejyo, F; Isono, M; Kanoh, H; Kiriyama, T; Koyama, A; Kurumatani, H; Okada, K; Origasa, H; Yamada, S, 2015
)
1.41
"Beraprost sodium (BPS) is a chemically stable and orally active prostacyclin analog that is used in the treatment of chronic arterial occlusive disease since 1992 and primary pulmonary hypertension since 1999 in Japan. "( Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Ando, A; Miyamoto, Y; Oshida, K; Seya, K; Shimamura, M, 2017
)
2.16
"Beraprost sodium (BPS) is a stable orally active prostacyclin analogue with vasodilatory and anti-platelet effects, and has been widely used as therapeutics for pulmonary artery hypertension and chronic arterial obstruction. "( Novel effects of beraprost sodium on vasculatures.
Ito, S; Kudo, M; Matsuda, K; Saito, A; Sugawara, A; Uruno, A, 2010
)
2.14
"Beraprost sodium (BPS) is a stable, orally active prostaglandin I(2) (PGI(2) ) analog with antiplatelet and vasodilating properties. "( Beraprost sodium, an orally active prostaglandin I(2) analog, improves renal anemia in hemodialysis patients with peripheral arterial disease.
Hidaka, S; Honda, K; Ikee, R; Ishioka, K; Kobayashi, S; Maesato, K; Moriya, H; Ohtake, T; Oka, M, 2010
)
3.25
"Beraprost sodium is an orally active prostaglandin (PG)I(2) analogue, which has antiplatelet and vasodilating properties. "( Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus.
Goya, K; Kasayama, S; Otsuki, M; Xu, X, 2003
)
2.03
"Beraprost sodium (BPS) is an analogue of PGI2 that is more stable than parental PGI2 in vivo (t1/2 for BPS is > 1 h vs."( Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium.
Akaike, T; Beppu, T; Fang, J; Maeda, H; Ogawa, M; Sawa, T; Tanaka, S; Wu, J, 2003
)
1.25
"Beraprost sodium (BPS) is an orally active prostacyclin analogue. "( Effect of long-term administration of a prostacyclin analogue (beraprost sodium) on myocardial fibrosis in Dahl rats.
Fukushima, A; Ida, N; Kaneshige, T; Saida, Y; Soda, A; Takenaka, M; Tanaka, R; Yamane, Y, 2007
)
2.02
"Beraprost sodium (BPS) is an orally stable analogue of prostacyclin that inhibits adenylate-cyclase-dependent platelet aggregation and is proposed for treatment of chronic arterial occlusion. "( Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers.
Demolis, JL; Funck-Brentano, C; Jaillon, P; Mouren, M; Robert, A, 1993
)
1.97
"Beraprost sodium is a chemically stable prostaglandin I2 analogue with antiplatelet and vasodilator actions. "( Reduction of progressive burn injury by a stable prostaglandin I2 analogue, beraprost sodium (Procylin): an experimental study in rats.
Battal, MN; Hata, Y; Ito, O; Kawazoe, T; Matsuda, H; Matsuka, K; Yoshida, Y, 1996
)
1.97
"Beraprost appears to be an effective and available substitute for NO and tolazoline in screening for pulmonary vasodilator responsiveness."( Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children.
Fukahara, K; Hamamichi, Y; Hashimoto, I; Ichida, F; Miyawaki, T; Murakami, A; Tsubata, S; Uese, K, 1997
)
1.02
"Beraprost sodium is a chemically stable prostaglandin I2 (PGI2) analogue with antiplatelet, vasodilator and cytoprotective actions."( Effect of a prostaglandin I2 analogue, beraprost sodium, on burn-induced gastric mucosal injury in rats.
Battal, MN; Hata, Y; Ito, O; Kawazoe, T; Matsuda, H; Matsuka, K; Nagao, M; Yoshida, Y, 1997
)
1.29
"Beraprost sodium is a stable analog of the vasodilator, platelet antiaggregatory eicosanoid, prostacyclin. "( Beneficial action of beraprost sodium, a prostacyclin analog, in stroke-prone rats.
Belmonte, A; Chander, PN; Inamdar, RS; Mistry, M; Stier, CT, 1997
)
2.06
"Beraprost sodium (BPS) is a new stable, orally active prostaglandin I(2) analogue with antiplatelet and vasodilating properties. "( Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group.
Besse, B; Boissel, JP; Fiessinger, JN; Lièvre, M; Morand, S, 2000
)
2.26
"Beraprost sodium (BPS) is a prostaglandin I2 analogue, is stable in aqueous solution, and has a cytoprotective effect on various types of cells."( Increased islet viability by addition of beraprost sodium to collagenase solution.
Arita, S; Kasraie, A; Kawahara, T; Mullen, Y; Ohtsuka, S; Smith, CV; Une, S, 2001
)
1.3
"Beraprost is a well tolerated agent."( Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.
Goa, KL; Melian, EB, 2002
)
2.48

Effects

Beraprost sodium has been shown to have positive effects in the kidney. Its efficacy and safety in the treatment of nephrotic syndrome (NS) are currently unknown.

ExcerptReferenceRelevance
"Beraprost has a variety of biological activities such as antiplatelet effects, vasodilation effects, antiproliferative effects on vascular smooth muscle cells, cytoprotective effects on endothelial cells and inhibitory effects on the production of inflammatory cytokines."( [Pharmacological and clinical properties of beraprost sodium, orally active prostacyclin analogue].
Kurumatani, H; Nishio, S, 2001
)
1.29
"Beraprost sodium has been shown to have positive effects in the kidney; however, its efficacy and safety in the treatment of nephrotic syndrome (NS) are currently unknown. "( Clinical efficacy and safety of beraprost sodium in the treatment of nephrotic syndrome: A meta-analysis.
Fang, X; Ke, B; Yan, P, 2023
)
2.64
"Beraprost sodium (BPS) has been shown to be effective in patients with pulmonary hypertension."( Beraprost Upregulates KV Channel Expression and Function via EP4 Receptor in Pulmonary Artery Smooth Muscle Cells Obtained from Rats with Hypoxia-Induced Pulmonary Hypertension.
Deng, J; Fan, F; Geng, J; Tian, H, 2019
)
2.68

Actions

Beraprost reduced lower limb ischemic symptoms, IMT, and the incidence of cardiovascular events in patients with ASO. Beraprost sodium inhibit platelet aggregation induced by adenosine 5'-diphosphate (ADP), collagen and arachidonic acid.

ExcerptReferenceRelevance
"Beraprost reduced lower limb ischemic symptoms, IMT, and the incidence of cardiovascular events in patients with ASO."( Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients.
Arai, T, 2013
)
2.15
"Beraprost sodium inhibit platelet aggregation induced by adenosine 5'-diphosphate (ADP), collagen and arachidonic acid."( [Research and development of beraprost sodium, a new stable PGI2 analogue].
Aoki, S; Kanbayashi, Y; Kanou, K; Nagase, H; Nishio, S, 1997
)
1.31
"Beraprost was able to inhibit fetal bovine serum-stimulated proliferation of mesangial cells in concentrations enough to increase cellular cAMP."( Beraprost sodium, an analogue of prostacyclin, induces the expression of mitogen-activated protein kinase phosphatase and inhibits the proliferation of cultured mesangial cells.
Araki, S; Haneda, M; Hidaka, H; Isono, M; Kashiwagi, A; Kikkawa, R; Sugimoto, T; Togawa, M; Yasuda, H, 1997
)
2.46

Treatment

Pretreatment with beraprost attenuated AGML and downregulated the expression of HNE and HO-1, while sensory denervation aggravated AGML. Beraprost sodium treatment attenuated hepatic steatosis, induced the transcription of genes involved in lipid metabolism in C57BL/6 mice (P<0.05), and increased theexpression of hepatic SIRT1 and peroxisome proliferator activated receptor α (PPARα) in the cells treated with fructose.

ExcerptReferenceRelevance
"Beraprost sodium treatment attenuated hepatic steatosis, induced the transcription of genes involved in lipid metabolism in C57BL/6 mice (P<0.05), and increased the expression of hepatic SIRT1 and peroxisome proliferator activated receptor α (PPARα) in the cells treated with fructose. "( Beraprost sodium, a prostacyclin analogue, reduces fructose-induced hepatocellular steatosis in mice and in vitro via the microRNA-200a and SIRT1 signaling pathway.
Cao, X; Guan, H; Huang, Z; Li, Y; Liao, Z; Liu, J; Liu, L; Xiao, H; Xu, L; Zhang, P, 2017
)
3.34
"Beraprost sodium treatment was well tolerated and safe in cats with CKD. "( A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease.
Iio, A; Kurumatani, H; Sakamoto, T; Sato, R; Takenaka, M, 2018
)
2.15
"Beraprost-treated B cells potently stimulated allogeneic T cells, which was significantly abolished by CD86 neutralization."( Beraprost enhances the APC function of B cells by upregulating CD86 expression levels.
Choe, J; Jeoung, DI; Kim, J; Kim, YM; Park, CH; Park, CS, 2011
)
2.53
"Beraprost sodium treatment significantly decreased the proliferation and ROS levels of RMCs cultured in high glucose conditions in a dose-dependent manner (p < 0.05)."( Effects of beraprost sodium, a prostaglandin I(2) analog, on high glucose-induced proliferation and oxidative stress in a rat glomerular mesangial cell line.
Liu, ZM; Zhang, LY; Zou, JJ, 2011
)
1.48
"Beraprost sodium treatment inhibited the increase in urinary protein, serum creatinine and blood urea nitrogen, and the decrease in creatinine clearance."( Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model.
Kurumatani, H; Matsushita, T; Sasaki, R; Sato, N; Suzuki, M; Tamura, M; Yamada, M, 2002
)
1.38
"In beraprost-treated preparations, the decrease of the myocardial K+ content during hypoxia was inhibited."( Effect of beraprost sodium on changes in action potentials during hypoxia as compared with propranolol, diltiazem and glibenclamide in guinea-pig ventricular muscle.
Nishio, S; Shigenobu, K; Ueno, Y,
)
1.05
"Pretreatment with beraprost attenuated AGML and downregulated the expression of HNE and HO-1, while sensory denervation aggravated AGML and upregulated the expression of HNE and HO-1."( Adaptive HNE-Nrf2-HO-1 pathway against oxidative stress is associated with acute gastric mucosal lesions.
Ichinose, M; Ito, T; Kimura, H; Oka, M; Shimizu, Y; Tsuruo, Y; Ueda, K; Ueyama, T; Yoshida, K, 2008
)
0.67
"Post-treatment with beraprost (100 microg/kg p.o.) 4.5 h after pMCAO also significantly decreased neurological deficits and infarct volume in WT mice."( Neuroprotective properties of prostaglandin I2 IP receptor in focal cerebral ischemia.
Doré, S; Maruyama, T; Narumiya, S; Saleem, S; Shah, ZA, 2010
)
0.68
"Treatment with beraprost increased the number of GFP/von Willebrand factor-double-positive cells in the ischemic myocardium."( Beraprost sodium enhances neovascularization in ischemic myocardium by mobilizing bone marrow cells in rats.
Ishino, K; Kangawa, K; Kitamura, S; Miyahara, Y; Mori, H; Nagaya, N; Obata, H; Ohnishi, S; Sano, S, 2006
)
2.12
"Treatment with Beraprost resulted in a rapid activation of cellular cyclic AMP-dependent protein kinase (PKA)."( Inhibitory effect of a synthetic prostacyclin analogue, beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells.
Fujimaki, M; Hayakawa, Y; Higashiyama, K; Niiya, K; Nomura, N; Ozawa, T; Sakuragawa, N; Shinbo, M, 1996
)
0.88

Toxicity

The addition of oral sildenafil to beraprost appears to represent a safe and effective therapeutic option, at least in the acute phase, for patients with pulmonary hypertension. The pentoxifylline and cilostazol was associated with a lower ratio of adverse events than berap Frost combined with them.

ExcerptReferenceRelevance
" Addition of oral sildenafil to beraprost appears to represent a safe and effective therapeutic option, at least in the acute phase, for patients with pulmonary hypertension."( Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension.
Ikeda, D; Ishimaru, S; Itoh, N; Kamigaki, M; Nishimura, M; Ohira, H; Sakaue, S; Tsujino, I, 2005
)
0.9
"Ambrisentan is considered as safe and effective for Japanese adults with PAH."( Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Iwase, T; Nakahara, N; Nakajima, H; Shimamura, R; Shirato, K; Yoshida, S, 2011
)
0.37
" The outcome measures were walking distance measured by treadmill (maximum and pain-free walking distance), ankle-brachial index and adverse events."( Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis.
Cao, Y; Liang, X; Wang, Y; Zhao, C, 2022
)
0.95
" The pentoxifylline and cilostazol was associated with a lower ratio of adverse events than beraprost and cilostazol combined with beraprost."( Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis.
Cao, Y; Liang, X; Wang, Y; Zhao, C, 2022
)
1.17

Pharmacokinetics

ExcerptReferenceRelevance
" Secondarily, pharmacodynamic measurements of coagulation (prothrombin time, and International Normalised Ratio, INR) and platelet function (in vitro closure time assessed by PFA-100) were performed."( Beraprost sodium-fluindione combination in healthy subjects: pharmacokinetic and pharmacodynamic aspects.
Ankri, A; Aymard, G; Berlin, I; Besse, B; Diquet, B; Fabry, C; Lechat, P; Warot, D,
)
1.57

Compound-Compound Interactions

Beraprost sodium (BPS) is a chemically stable and orally active prostacyclin analogue. It is used for the treatment of chronic occlusive disease and primary pulmonary hypertension. This study investigated the drug-drug interaction mediated by cytochrome P450.

ExcerptReferenceRelevance
"Beraprost sodium (BPS), a chemically stable and orally active prostacyclin analogue used for the treatment of chronic occlusive disease and primary pulmonary hypertension, was investigated in terms of its drug-drug interaction mediated by cytochrome P450."( Evaluation of drug-drug interaction potential of beraprost sodium mediated by P450 in vitro.
Fukazawa, T; Miyamoto, Y; Yajima, K, 2008
)
2.04
"BACKGROUND To explore the efficacy of beraprost sodium combined with sildenafil and its effects on the vascular endothelial function and inflammation in left heart failure patients complicated with pulmonary arterial hypertension."( Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension.
Gao, B; Sun, D; Wang, Z; Yang, W, 2021
)
1.27

Dosage Studied

beraprost significantly inhibited the formation of lipid peroxides in the brain and serum induced by cerebral ischemia. Inconvenient intravenous dosing of prostacyclin led to the development of more stable, an orally active analogue.

ExcerptRelevanceReference
" Concentrations of TRK-100, a stable analog of PGI2, equipotent to those of PGI2 released by ANG II, estimated from dose-response curves for TRK-100 and enhancement by indomethacin of ANG II-induced contractions, did not differ in proximal and distal portions."( Comparison of the response to angiotensin II of isolated dog coronary and mesenteric arteries of proximal and distal portions.
Minami, Y; Toda, N,
)
0.13
" Optimal activity was observed 30-60 min after dosing and activity was sustained throughout the experimental period."( Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation.
Cleland, ME; McCraw, AP; Nishio, S; Sim, AK; Umetsu, T, 1985
)
0.27
" In a dosage of 25 micrograms kg-1 or higher, beraprost, administered orally, significantly inhibited the formation of lipid peroxides in the brain and serum induced by cerebral ischemia and subsequent recirculation in a dose-dependent manner."( Inhibitory effect of beraprost sodium on formation of lipid peroxides in ischemia and recirculation-induced cerebral injury.
Endoh, T; Kainoh, M; Nakadate, T; Ueno, S,
)
0.71
" By pretreatment with 13-azaprostanoic acid (13-APA), a TXA2/endoperoxide receptor antagonist, the dose-response curve of BPS in the veins was shifted to the right."( The contractile mechanism of beraprost sodium, a stable prostacyclin analog, in the isolated canine femoral vein.
Ishikawa, M; Namiki, A, 1994
)
0.58
" The optimal dose remains uncertain, but the initial dosage of 40-60 micrograms/day given in three to four doses for adult patients is considered to be acceptable."( [Short- and long-term effects of the new oral prostacyclin analogue, beraprost sodium, in patients with severe pulmonary hypertension].
Hashiguchi, R; Matsuo, N; Matsuura, H; Morishita, T; Muto, H; Nakayama, T; Ozawa, Y; Saito, T; Saji, T; Yamazaki, J, 1996
)
0.53
" Inconvenient intravenous dosing of prostacyclin led to the development of more stable, an orally active analogue: beraprost."( Orally active prostacyclin analogue for cardiovascular disease.
Nagaya, N, 2010
)
0.57
" Pharmacokinetics in these Japanese patients was similar to that of non-Japanese populations, suggesting that once-daily dosing is appropriate in Japanese patients."( Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension.
Iwase, T; Nakahara, N; Nakajima, H; Shimamura, R; Shirato, K; Yoshida, S, 2011
)
0.37
" The use of these medications is challenging due to complexity in dosing and their side effect profiles which limit patient tolerability and acceptance."( What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
El Yafawi, R; Wirth, JA, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
prostaglandin receptor agonistAn agonist that binds to and activates prostaglandin receptors.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
secondary allylic alcoholAn allylic alcohol in which the carbon atom that links the double bond to the hydroxy group is also attached to one other carbon and one hydrogen.
enyneAn acetylenic and an olefinic compound containing a carbon chain that contains a carbon-carbon double bond and a carbon-carbon triple bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (386)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (4.15)18.7374
1990's108 (27.98)18.2507
2000's138 (35.75)29.6817
2010's111 (28.76)24.3611
2020's13 (3.37)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 51.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index51.42 (24.57)
Research Supply Index6.15 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index82.63 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (51.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials61 (14.99%)5.53%
Reviews43 (10.57%)6.00%
Case Studies34 (8.35%)4.05%
Observational4 (0.98%)0.25%
Other265 (65.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (20)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure [NCT03682952]Phase 4100 participants (Anticipated)Interventional2018-02-01Active, not recruiting
An Open-label Extension of BPS-314d-MR-PAH-302 in Pulmonary Arterial Hypertension Patients [NCT03657095]Phase 3112 participants (Actual)Interventional2018-12-10Terminated(stopped due to The pivotal study, BPS-314d-MR-PAH-302 (NCT01908699), failed to demonstrate efficacy.)
Effect of Beraprost Sodium (Berasil) on Hemodialysis [NCT03142360]60 participants (Anticipated)Interventional2017-04-05Recruiting
Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Pulmonary Arterial Hypertension Children Associated With Left to Right Shunt Congenital Heart Defect [NCT03431649]Phase 440 participants (Actual)Interventional2017-04-01Completed
An Open-label Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients [NCT00990314]Phase 231 participants (Actual)Interventional2009-11-30Completed
[NCT02480751]Phase 2113 participants (Actual)Interventional2005-10-31Completed
TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis) [NCT01090037]Phase 2/Phase 3892 participants (Actual)Interventional2010-03-31Completed
TRK-100STP Pharmacokinetic Study in Healthy Volunteers - Evaluation of Pharmacokinetic Interaction Between TRK-100STP and Kremezin [NCT00719758]Phase 124 participants (Actual)Interventional2008-06-30Completed
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients. [NCT00792571]Phase 218 participants (Actual)Interventional2009-02-28Completed
A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients [NCT00781885]Phase 219 participants (Actual)Interventional2009-01-31Completed
The Effect of Prostaglandin I2 (Beraprost Na), Administered Orally for Eight Weeks, on the Endothelial Cell Functional Disorder in Type II Diabetes Mellitus Patients With Symptoms of a Minute Peripheral Blood Flow Disorder [NCT01061060]Phase 4110 participants (Actual)Interventional2010-01-31Completed
Compassionate Use of Beraprost Sodium 314d Modified Release (BPS-314d-MR) for Three Patients With Pulmonary Arterial Hypertension (PAH). [NCT01966302]Phase 21 participants (Actual)Interventional2013-11-30Completed
A Pharmacokinetic Study of TRK-100STP -A Single Oral Administration Study in Japanese, Chinese, and South Korean Non-elderly Healthy Adult Males - [NCT01423435]Phase 136 participants (Actual)Interventional2011-08-31Completed
Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients [NCT02786979]Phase 4190 participants (Actual)Interventional2010-07-31Terminated(stopped due to Upon interim analysis, sponsor's decision due to absence of demonstration of efficacy.)
Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study) [NCT01796418]102 participants (Anticipated)Interventional2013-03-31Recruiting
A Pharmacokinetic Study of TRK-100STP -A Single Oral Administration Study in Japanese Patients With Renal Impairment as Compared to Subjects With Normal Renal Function [NCT01443429]Phase 124 participants (Actual)Interventional2011-08-31Completed
A Multinational, Multicenter, Double-blind, Randomized, Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagon [NCT01458236]Phase 30 participants (Actual)Interventional2011-11-30Withdrawn
A 12-week, Double-blind, International, Multicenter, Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) [NCT00989963]Phase 236 participants (Actual)Interventional2010-02-01Completed
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension [NCT01908699]Phase 3273 participants (Actual)Interventional2013-05-31Completed
Protective Effect of Beraprost Sodium Tablets on Coronary Microcirculation Function and Ventricular Remodeling After Reperfusion Therapy for Acute ST Segment Elevation Myocardial Infarction [NCT05103813]Early Phase 1100 participants (Anticipated)Interventional2022-05-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00781885 (12) [back to overview]Change in Respiratory Rate From Baseline to Week 19
NCT00781885 (12) [back to overview]Change in Systolic Blood Pressure (SBP) From Baseline to Week 19
NCT00781885 (12) [back to overview]Apparent Clearance (CL/F) of BPS-MR
NCT00781885 (12) [back to overview]Apparent Volume of Distribution (Vz/F) of BPS-MR
NCT00781885 (12) [back to overview]Change in Body Mass Index (BMI) From Baseline to Week 19
NCT00781885 (12) [back to overview]Change in Body Temperature From Baseline to Week 19
NCT00781885 (12) [back to overview]Change in Diastolic Blood Pressure (DBP) From Baseline to Week 19
NCT00781885 (12) [back to overview]Change in Heart Rate From Baseline to Week 19
NCT00781885 (12) [back to overview]Change in Weight From Baseline to Week 19
NCT00781885 (12) [back to overview]Number of Participants That Reported at Least One Treatment-Emergent Adverse Event (TEAE)
NCT00781885 (12) [back to overview]Change in Electrocardiogram Intervals From Baseline to Week 19
NCT00781885 (12) [back to overview]Maximum Tolerated Dose (MTD) of BPS-MR in Pulmonary Arterial Hypertension (PAH) Patients, Following Chronic, Twice-daily Administration.
NCT00792571 (6) [back to overview]Change From Baseline in Borg Dyspnea Score at End of Study
NCT00792571 (6) [back to overview]Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at End of Study
NCT00792571 (6) [back to overview]Number of Participants Reporting at Least One Treatment-Emergent Adverse Event (TEAE)
NCT00792571 (6) [back to overview]Number of Treatment Emergent Adverse Events Reported During The Study
NCT00792571 (6) [back to overview]Number of Participants That Experienced Clinical Worsening During the Study
NCT00792571 (6) [back to overview]Number of Participants With a Change in WHO Functional Class
NCT00989963 (9) [back to overview]Change From Baseline in Cardiac Output (CO) at Week 12
NCT00989963 (9) [back to overview]Change From Baseline in Pulmonary Arterial Pressure at Week 12
NCT00989963 (9) [back to overview]Change From Baseline in Pulmonary Vascular Resistance at Week 12
NCT00989963 (9) [back to overview]Number of Participants With at Least One Post-baseline Clinically Significant Laboratory Value
NCT00989963 (9) [back to overview]Change in Borg Dyspnea Score From Baseline to Week 6 and Week 12
NCT00989963 (9) [back to overview]Change in Six Minute Walk Distance From Baseline to Week 6 and Week 12
NCT00989963 (9) [back to overview]N-Terminal ProB-type Natriuretic Peptide Level at Week 6 and Week 12
NCT00989963 (9) [back to overview]Number of Participants in Each World Health Organization (WHO) Functional Class for Pulmonary Arterial Hypertension (PAH) at Week 6 and 12
NCT00989963 (9) [back to overview]Number of Participants With Newly Occurring Clinically Significant ECG Abnormalities
NCT00990314 (5) [back to overview]Change in Borg Dyspnea Score
NCT00990314 (5) [back to overview]Change in Six-Minute-Walk Distance (6MWD)
NCT00990314 (5) [back to overview]Number of Reported Treatment-Emergent Adverse Events
NCT00990314 (5) [back to overview]Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)
NCT00990314 (5) [back to overview]Number of Participants That Experienced Clinical Worsening
NCT01908699 (5) [back to overview]Number of Participants With TEAEs, Serious TEAEs, Investigations SOC TEAEs, and Serious Investigations SOC TEAEs
NCT01908699 (5) [back to overview]Mean Change From Baseline in Borg Dyspnea Score at Week 24
NCT01908699 (5) [back to overview]Mean Change From Baseline in NT-pro-BNP Levels at Week 24
NCT01908699 (5) [back to overview]Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 24
NCT01908699 (5) [back to overview]Number of Participants That Experienced Clinical Worsening
NCT03657095 (2) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT03657095 (2) [back to overview]Number of Participants With a TEAE of N-terminal Pro-brain Natriuretic Peptide (NT-pro-BNP) Increased

Change in Respiratory Rate From Baseline to Week 19

Respiratory Rate was assessed at each study visit and taken after five minutes of seated rest. Respiratory rate was measured in breaths per minute. (NCT00781885)
Timeframe: Baseline and 19 weeks

InterventionBreaths per Minute (Mean)
Beraprost Sodium0.2

[back to top]

Change in Systolic Blood Pressure (SBP) From Baseline to Week 19

Systolic blood pressure was assessed at each study visit and taken after five minutes of seated rest. Systolic blood pressure was measured in millimeters of mercury (mmHg). (NCT00781885)
Timeframe: Baseline and 19 weeks

InterventionmmHg (Mean)
Beraprost Sodium0.6

[back to top]

Apparent Clearance (CL/F) of BPS-MR

Apparent clearance is defined as plasma clearance divided by absolute bioavailability per kilogram of bodyweight. (NCT00781885)
Timeframe: pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day 67

InterventionL/h/kg (Mean)
Beraprost Sodium1.51

[back to top]

Apparent Volume of Distribution (Vz/F) of BPS-MR

(NCT00781885)
Timeframe: pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8 and 12 hours post-dose on Day 67

InterventionLiters per kilogram (L/kg) (Mean)
Beraprost Sodium43.6

[back to top]

Change in Body Mass Index (BMI) From Baseline to Week 19

Body Mass Index (BMI) was assessed at each study visit and taken after five minutes of seated rest. Body mass index is a value derived from the mass and height of a person. The BMI is defined as the body mass divided by the square of the body height, and is universally expressed in units of kg/m², resulting from mass in kilograms and height in meters. (NCT00781885)
Timeframe: Baseline and 19 weeks

Interventionkilograms/meter^2 (Mean)
Beraprost Sodium-0.2

[back to top]

Change in Body Temperature From Baseline to Week 19

Body Temperature was assessed at each study visit and taken after five minutes of seated rest. Body temperature was measured in degrees Celsius (C). (NCT00781885)
Timeframe: Baseline and 19 weeks

Interventiondegrees Celsius (Mean)
Beraprost Sodium0.1

[back to top]

Change in Diastolic Blood Pressure (DBP) From Baseline to Week 19

Diastolic blood pressure was assessed at each study visit and taken after five minutes of seated rest. Diastolic blood pressure was measured in millimeters of mercury (mmHg). (NCT00781885)
Timeframe: Baseline and 19 weeks

InterventionmmHg (Mean)
Beraprost Sodium-2.5

[back to top]

Change in Heart Rate From Baseline to Week 19

Heart Rate was assessed at each study visit and taken after five minutes of seated rest. Heart rate is measured in beats per minute (BPM). (NCT00781885)
Timeframe: Baseline and 19 weeks

InterventionBeats per Minute (BPM) (Mean)
Beraprost Sodium0.7

[back to top]

Change in Weight From Baseline to Week 19

Weight was assessed at each study visit and taken after five minutes of seated rest. Weight was measured in kilograms (kg). (NCT00781885)
Timeframe: Baseline and 19 weeks

Interventionkg (Mean)
Beraprost Sodium-0.5

[back to top]

Number of Participants That Reported at Least One Treatment-Emergent Adverse Event (TEAE)

A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-201 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted (NCT00781885)
Timeframe: 19 Weeks

InterventionParticipants (Count of Participants)
Beraprost Sodium19

[back to top]

Change in Electrocardiogram Intervals From Baseline to Week 19

(NCT00781885)
Timeframe: Baseline and 19 weeks

Interventionmillisecond (msec) (Mean)
PR IntervalQRS IntervalQT IntervalQTc BazettQTc Friderica
Beraprost Sodium6.1-4.43.2-2.5-0.3

[back to top]

Maximum Tolerated Dose (MTD) of BPS-MR in Pulmonary Arterial Hypertension (PAH) Patients, Following Chronic, Twice-daily Administration.

(NCT00781885)
Timeframe: 10 Weeks

InterventionParticipants (Count of Participants)
120 mcg180 mcg240 mcg300 mcg420 mcg540 mcg600 mcg
Beraprost Sodium2232117

[back to top]

Change From Baseline in Borg Dyspnea Score at End of Study

The modified 0-10 category-ratio Borg scale consists of an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) and 10 (for the worst condition) with nonlinear spacing of verbal descriptors of severity corresponding to specific numbers. The participant chose the number or the verbal descriptor to reflect presumed ratio properties of sensation or symptom intensity. Baseline was defined as the last non-missing evaluation preceding the first dose of study drug in study BPS-MR-PAH-201. Only participants with both a measurement at baseline and at the given visit are presented. All efficacy results are descriptive; no statistical analysis was conducted. (NCT00792571)
Timeframe: Baseline and 56 months

Interventionscores on a scale (Mean)
Beraprost Sodium-0.09

[back to top]

Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at End of Study

"The area used for the Six Minute Walk Test (6MWT) was pre-measured at a minimum of 30 meters in length and at least 2 to 3 meters in width. There were no turns or significant curves to the 6-minute walk area. The length was marked with gradations to ensure the accurate measurement of the distance walked. The area was well ventilated with air temperature controlled at 20 to 23°C. Intermittent rest periods were allowed if the participant could no longer continue. If the participant needed to rest briefly, he/she could stand or sit and then begin again when rested but the clock continued to run. At the end of 6 minutes, the tester called stop while simultaneously stopping the watch and then measured the distance walked. For the purposes of the 6MWT if a participant was assessed at Baseline using oxygen therapy, then all future 6MWT were conducted in the same manner. All efficacy results are descriptive; no statistical analysis was conducted." (NCT00792571)
Timeframe: Baseline and 56 months

Interventionmeters (Mean)
Beraprost Sodium10.55

[back to top]

Number of Participants Reporting at Least One Treatment-Emergent Adverse Event (TEAE)

A treatment-emergent adverse event (TEAEs) is defined as an event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments. AEs occurring more than 3 days after the last day study drug is taken in the study will not be included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only treatment-emergent adverse events occurring during the treatment period of the BPS-MR-PAH-202 study will be summarized. Any adverse event starting prior to the first dose of study drug will be excluded from the summary analyses and only presented in the data listings. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00792571)
Timeframe: Up to 56 months

InterventionParticipants (Count of Participants)
Beraprost Sodium18

[back to top]

Number of Treatment Emergent Adverse Events Reported During The Study

A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for participants with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-202 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00792571)
Timeframe: Up to 56 months

InterventionTEAEs (Number)
Beraprost Sodium156

[back to top]

Number of Participants That Experienced Clinical Worsening During the Study

Number of Participants that experienced Clinical Worsening in the opinion of the Investigator. Clinical Worsening was defined as any of these events following the Baseline visit: Death, Transplantation or atrial septostomy, Clinical deterioration as defined by: Hospitalization as a result of PAH symptoms or Initiation of any new PAH specific therapy (e.g. ERA, PDE-5 inhibitor, prostanoid). All efficacy results are descriptive; no statistical analysis was conducted. (NCT00792571)
Timeframe: Up to 56 months

InterventionParticipants (Count of Participants)
DeathNew PAH TherapiesTransplantation or atrial septostomyHospitalization
Beraprost Sodium1600

[back to top]

Number of Participants With a Change in WHO Functional Class

Change from Baseline in participant clinical status was recorded according to the World Health Organization (WHO) Functional Class. A change from lower to higher functional class (i.e. 'III to IV' or 'II to III') was considered as a deterioration. A change from higher to lower functional class (i.e. 'III to II' or 'II to I') was considered as an improvement. All efficacy results are descriptive; no statistical analysis was conducted. (NCT00792571)
Timeframe: Baseline and 56 months

InterventionParticipants (Number)
Improved: Change from Class III to Class IINo Change in ClassDeteriorated: Change from Class II to Class IIINot Reported
Beraprost Sodium1746

[back to top]

Change From Baseline in Cardiac Output (CO) at Week 12

The change in Cardiac Output was evaluated from Baseline to Week 12. (NCT00989963)
Timeframe: Week 12

InterventionLiters per minute (L/min) (Mean)
Low Fixed Dose Group (60 ug)0.16
High Fixed Dose Group (240 ug)0.07
Maximum Tolerated Dose (MTD)0.35

[back to top]

Change From Baseline in Pulmonary Arterial Pressure at Week 12

The change in mean Pulmonary Arterial Pressure (mPAP) was evaluated from Baseline to Week 12. (NCT00989963)
Timeframe: 12 weeks

InterventionmmHg (Mean)
Low Fixed Dose Group (60 ug)0.42
High Fixed Dose Group (240 ug)-1.45
Maximum Tolerated Dose (MTD)4.10

[back to top]

Change From Baseline in Pulmonary Vascular Resistance at Week 12

The change in Pulmonary Vascular Resistance (PVR) was evaluated from Baseline to Week 12. PVR is expressed in Wood Units or millimeters of Mercury per Liter per minute (mmHG/L/min) (NCT00989963)
Timeframe: Week 12

InterventionWood Units (mmHg/L/min) (Mean)
Low Fixed Dose Group (60 ug)0.37
High Fixed Dose Group (240 ug)0.00
Maximum Tolerated Dose (MTD)0.13

[back to top]

Number of Participants With at Least One Post-baseline Clinically Significant Laboratory Value

Post-baseline clinically significant values, as defined by the Investigator, for hematology, serum chemistry, coagulation and urinalysis parameters were summarized. (NCT00989963)
Timeframe: Up to Week 12

Interventionparticipants (Number)
Low Fixed Dose Group (60 ug)5
High Fixed Dose Group (240 ug)3
Maximum Tolerated Dose (MTD)3

[back to top]

Change in Borg Dyspnea Score From Baseline to Week 6 and Week 12

The modified 0-10 category-ratio Borg scale consists of an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) and 10 (for the worst condition) with nonlinear spacing of verbal descriptors of severity corresponding to specific numbers. The participant chose the number or the verbal descriptor to reflect presumed ratio properties of sensation or symptom intensity. Only participants with both a measurement at baseline and at the given visit are presented. All efficacy results are descriptive; no statistical analysis was conducted. (NCT00989963)
Timeframe: Baseline, Week 6 and 12

,,
Interventionscores on a scale (Mean)
Week 6Week 12 at peakWeek 12 at trough
High Fixed Dose Group (240 ug)0.680.641.11
Low Fixed Dose Group (60 ug)0.710.500.45
Maximum Tolerated Dose (MTD)0.800.400.67

[back to top]

Change in Six Minute Walk Distance From Baseline to Week 6 and Week 12

"Area used for the Six Minute Walk Test (6MWT) was pre-measured at 30 meters in length. Rest periods were allowed if patient could no longer continue. If patient needed to rest, he/she could stand or sit and then begin again when rested but the clock continued to run. At the end of 6 minutes, the tester called stop while stopping the watch and then measured the distance walked. For purposes of the 6MWT, if patient was assessed at Baseline using oxygen therapy, all future 6MWT were conducted in the same manner. All efficacy results are descriptive; no statistical analysis was conducted." (NCT00989963)
Timeframe: Baseline, Week 6 and 12

,,
Interventionmeters (Mean)
Week 6 PeakWeek 12 PeakWeek 12 Trough
High Fixed Dose Group (240 ug)29.9142.1847.67
Low Fixed Dose Group (60 ug)2.1752.8244.00
Maximum Tolerated Dose (MTD)39.9047.1011.67

[back to top]

N-Terminal ProB-type Natriuretic Peptide Level at Week 6 and Week 12

NT-proBNP functions as a strong indicator of prognosis in patients with pulmonary arterial hypertension. (NCT00989963)
Timeframe: Week 6 and Week 12

,,
Interventionnanograms per Liter (ng/L) (Mean)
Week 6Week 12
High Fixed Dose Group (240 ug)5.826.06
Low Fixed Dose Group (60 ug)6.386.33
Maximum Tolerated Dose (MTD)6.836.85

[back to top]

Number of Participants in Each World Health Organization (WHO) Functional Class for Pulmonary Arterial Hypertension (PAH) at Week 6 and 12

WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). (NCT00989963)
Timeframe: Week 6 and Week 12

,,
InterventionParticipants (Count of Participants)
Week 6: Class IWeek 6: Class IIWeek 6: Class IIIWeek 6: Class IVWeek 12: Class IWeek 12: Class IIWeek 12: Class IIIWeek 12: Class IV
High Fixed Dose Group (240 ug)03801460
Low Fixed Dose Group (60 ug)16501560
Maximum Tolerated Dose (MTD)03700370

[back to top]

Number of Participants With Newly Occurring Clinically Significant ECG Abnormalities

Clinically significant ECG abnormalities at Baseline only are excluded. (NCT00989963)
Timeframe: Up to 12 weeks

,,
InterventionParticipants (Number)
Right Atrial AbnormalityChronic Pulmonary Disease PatternLow QRS VoltageNon-Specific ST-T Changes
High Fixed Dose Group (240 ug)2100
Low Fixed Dose Group (60 ug)0000
Maximum Tolerated Dose (MTD)0011

[back to top]

Change in Borg Dyspnea Score

The modified 0-10 category-ratio Borg scale consists of an 11-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) and 10 (for the worst condition) with nonlinear spacing of verbal descriptors of severity corresponding to specific numbers. The participant chose the number or the verbal descriptor to reflect presumed ratio properties of sensation or symptom intensity. Baseline was defined as the last non-missing evaluation preceding the first dose of study drug in study BPS-MR-PAH-203. Only participants with both a measurement at baseline and at the given visit are presented. All efficacy results are descriptive; no statistical analysis was conducted. (NCT00990314)
Timeframe: Baseline and 42 months

Interventionscores on a scale (Mean)
Beraprost Sodium0.86

[back to top]

Change in Six-Minute-Walk Distance (6MWD)

"Area used for the Six Minute Walk Test (6MWT) was pre-measured at 30 meters in length. Rest periods were allowed if patient could no longer continue. If patient needed to rest, he/she could stand or sit and then begin again when rested but the clock continued to run. At the end of 6 minutes, the tester called stop while stopping the watch and then measured the distance walked. For purposes of the 6MWT, if patient was assessed at Baseline using oxygen therapy, all future 6MWT were conducted in the same manner. All efficacy results are descriptive; no statistical analysis was conducted." (NCT00990314)
Timeframe: Baseline and 42 months

Interventionmeters (Mean)
Beraprost Sodium24.09

[back to top]

Number of Reported Treatment-Emergent Adverse Events

A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-204 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted. (NCT00990314)
Timeframe: Up to 42 months

InterventionTEAEs (Number)
Beraprost Sodium230

[back to top]

Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE)

A treatment-emergent adverse event (TEAE) is defined as an event not present prior to the initiation of the treatment or any event already present that worsens in either intensity or frequency following exposure to the treatment. AEs occurring more than 3 days after the last day study drug was taken in the study was not included in the statistical analyses or summaries (except for subjects with adverse events leading to study drug withdrawn). Only TEAEs that occurred during the treatment period of the BPS-MR-PAH-204 study were summarized. Any adverse event starting prior to the first dose of study drug was excluded from the summary analyses and only presented in the data listings. All efficacy results are descriptive; no statistical analysis was conducted (NCT00990314)
Timeframe: Up to 42 months

InterventionParticipants (Count of Participants)
Beraprost Sodium27

[back to top]

Number of Participants That Experienced Clinical Worsening

Number of Participants that experienced Clinical Worsening in the opinion of the Investigator. Clinical Worsening was defined as any of these events following the Baseline visit: Death, Transplantation or atrial septostomy, Clinical deterioration as defined by: Hospitalization as a result of PAH symptoms or Initiation of any new PAH specific therapy (e.g. ERA, PDE-5 inhibitor, prostanoid). All efficacy results are descriptive; no statistical analysis was conducted. (NCT00990314)
Timeframe: Up to 42 months

InterventionParticipants (Count of Participants)
DeathHospitalization As A Result of PAH SymptomsNew PAH TherapiesTransplantation or atrial septostomy
Beraprost Sodium1240

[back to top]

Number of Participants With TEAEs, Serious TEAEs, Investigations SOC TEAEs, and Serious Investigations SOC TEAEs

The number of participants experiencing overall Treatment-Emergent Adverse Adverse Events (TEAEs), serious TEAEs, Investigations SOC TEAEs, and serious Investigations SOC TEAEs were reported.Investigations SOC TEAEs were any event categorized within the Investigations System Order Class (SOC) and include adverse events due to physical examinations, vital signs, clinical laboratory parameters, and electrocardiogram findings. (NCT01908699)
Timeframe: up to 144 weeks

,
InterventionParticipants (Number)
at least 1 TEAEat least 1 Serious TEAEsat least 1 Investigations SOC TEAEsat least 1 Investigations SOC Serious TEAEs
Esuberaprost13575612
Placebo13278491

[back to top]

Mean Change From Baseline in Borg Dyspnea Score at Week 24

The Borg dyspnea score was assessed prior to and following the completion of the 6MWT at Week 24. The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (for the best condition) to 10 (for the worst condition). (NCT01908699)
Timeframe: Baseline and Week 24

Interventionscores on a scale (Mean)
Esuberaprost-0.10
Placebo-0.26

[back to top]

Mean Change From Baseline in NT-pro-BNP Levels at Week 24

Plasma NT-proBNP concentration is a useful biomarker for PAH as it is associated with changes in right heart morphology and function. (NCT01908699)
Timeframe: Baseline and Week 24

Interventionpicomole per liter (pmol/L) (Mean)
Esuberaprost12.38
Placebo20.48

[back to top]

Mean Change From Baseline in Six Minutes Walk Distance (6MWD) at Week 24

"Area used for the Six Minute Walk Test (6MWT) was pre-measured at 30 meters in length. Rest periods were allowed if patient could no longer continue. If patient needed to rest, he/she could stand or sit and then begin again when rested but the clock continued to run. At the end of 6 minutes, the tester called stop while stopping the watch and then measured the distance walked. For purposes of the 6MWT, if patient was assessed at Baseline using oxygen therapy, all future 6MWT were conducted in the same manner." (NCT01908699)
Timeframe: Baseline and Week 24

Interventionmeters (Mean)
Esuberaprost13.47
Placebo19.32

[back to top]

Number of Participants That Experienced Clinical Worsening

"The number of participants that experienced a Clinical Worsening event confirmed by Endpoint Adjudication Committee at First Maximum Severity. Clinical Worsening was defined as any of these events following the Baseline visit: Death (all causes); Hospitalization due to worsening PAH; Initiation of a parenteral (infusion or sub-cutaneous) prostacyclin, directly related to worsening PAH; Disease progression; Unsatisfactory long-term clinical response.~The number of participants that experienced clinical worsening is presented; time to clinical worsening data was not measured. Given the rate of clinical worsening overall and the large number of censored observations at the end of the study, the mean survival time estimates were not available for this endpoint." (NCT01908699)
Timeframe: up to 144 weeks

,
InterventionParticipants (Count of Participants)
Death (all causes)Hospitalization due to worsening PAHInitiation of a parenteral prostacyclinDisease progressionUnsatisfactory long-term clinical response
Esuberaprost823765
Placebo13141347

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAEs)

A TEAE is any untoward medical occurrence or undesirable event(s) experienced in a participant that begins or worsens following administration of study drug, whether or not considered related to study drug by Investigator. A serious adverse event (SAE) is an adverse event (AE) resulting in any of the following outcomes or deemed significant for any other reason, death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), or persistent or significant disability/incapacity. AEs included both SAEs and non-serious AEs. AEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 20.1. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module. (NCT03657095)
Timeframe: Baseline up to Month 7

,
InterventionParticipants (Count of Participants)
TEAEsTreatment-Emergent SAEs
Esuberaprost569
Placebo/Esuberaprost528

[back to top]

Number of Participants With a TEAE of N-terminal Pro-brain Natriuretic Peptide (NT-pro-BNP) Increased

A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module. (NCT03657095)
Timeframe: Baseline up to Month 7

InterventionParticipants (Count of Participants)
Esuberaprost5
Placebo/Esuberaprost2

[back to top]